TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor typesand has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.

Biotechnology

Clinical Trials

Health Care

Life Sciences

Pharmaceutical

Therapeutics

TransCode Therapeutics, Inc.

Michael Dudley

Subrata Ghosh, MS, PhD.

Neil Robertson

Zdravka Medarova

Tom Fitzgerald

Sue Duggan,RN MBA

Alan Freidman

TransCode Therapeutics, Inc.

Org chart

Similar companies